Misplaced Pages

Tropicamide/phenylephrine, sold under the brand name Mydcombi is a fixed dose combination of tropicamide and phenylephrine used to dilate the eyes (mydriasis). It contains, tropicamide, an anticholinergic, and phenylephrine, as the hydrochloride, an alpha-1 adrenergic receptor agonist. It is sprayed into the eyes.

It was approved for medical use in the United States in May 2023.

Medical uses

Tropicamide/phenylephrine is used for the short-term dilation of the pupils.

References

1. ^ https://mydcombi.com/wp-content/uploads/2023/05/MydCombi-PI-05072023.pdf
2. "Mydcombi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 8 May 2023.
3. "Eyenovia Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company's Proprietary Optejet Device Platform". Eyenovia. 8 May 2023. Retrieved 8 May 2023.

External links

• Clinical trial number NCT03751631 for "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-1)" at ClinicalTrials.gov
• Clinical trial number NCT03751098 for "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-2)" at ClinicalTrials.gov

• Medicine

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Alpha-1 adrenergic receptor agonists
• Combination drugs
• Muscarinic antagonists
• Ophthalmology drugs
• Pharmacology stubs